Teva Pharmaceutical Industries (TEVA) Upgraded at Mizuho

Mizuho upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a neutral rating to a buy rating in a research report released on Tuesday, MarketBeat.com reports. Mizuho currently has $23.00 price target on the stock, up from their prior price target of $19.12.

Several other research analysts also recently commented on TEVA. BTIG Research upgraded Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $24.00 price objective on the stock in a report on Monday, September 11th. Cantor Fitzgerald set a $17.00 price objective on Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Monday, September 11th. Jefferies Group reduced their price objective on Teva Pharmaceutical Industries from $21.00 to $18.50 and set a hold rating on the stock in a report on Tuesday, September 12th. Oppenheimer restated a hold rating on shares of Teva Pharmaceutical Industries in a report on Monday, September 11th. Finally, BidaskClub upgraded Teva Pharmaceutical Industries from a strong sell rating to a sell rating in a report on Wednesday, September 13th. Eight investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $21.17.

Teva Pharmaceutical Industries (NYSE:TEVA) traded up $0.33 on Tuesday, reaching $22.07. The company’s stock had a trading volume of 40,539,275 shares, compared to its average volume of 25,730,000. The stock has a market cap of $21,730.00, a P/E ratio of -3.76, a P/E/G ratio of 1.55 and a beta of 0.54. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $37.94. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

A number of hedge funds have recently made changes to their positions in TEVA. Schwab Charles Investment Management Inc. grew its stake in Teva Pharmaceutical Industries by 7.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after buying an additional 17,116 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in Teva Pharmaceutical Industries by 1.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock worth $1,416,000 after buying an additional 611 shares during the last quarter. Prudential Financial Inc. grew its stake in Teva Pharmaceutical Industries by 0.9% during the 2nd quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock worth $2,590,000 after buying an additional 730 shares during the last quarter. Principal Financial Group Inc. grew its stake in Teva Pharmaceutical Industries by 21.1% during the 2nd quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock worth $4,125,000 after buying an additional 21,658 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $6,560,000. Hedge funds and other institutional investors own 51.98% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/teva-pharmaceutical-industries-teva-upgraded-at-mizuho.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply